Long-term benefits to psychological health and well-being after ceremonial use of Ayahuasca in Middle Eastern and North African immigrants and refugees
This longitudinal online survey study (n=15) of mainly female Middle Eastern and North African immigrants and refugees found that ceremonial ayahuasca use was linked to better mental health, well-being and psychological functioning, including less depression, anxiety and shame. Most participants reported no lasting adverse effects and described positive changes that lasted for months.
Authors
- Lowe, M. X.
- Kettner, H.
- Jolly, D. R. P.
Published
Abstract
Background
Refugees and immigrants can experience complex stressors from the process of immigration that can have lasting and severe long-term mental health consequences. Experiences after ayahuasca ingestion are shown to produce positive effects on psychological wellbeing and mental health, including anecdotal reports of improved symptoms of trauma and related disorders. However, data on the longitudinal health impact of naturalistic ayahuasca use in Middle Eastern and North African (MENA) immigrant and refugee populations is limited.
Aims
The current longitudinal online survey study was conducted to gather prospective data on ceremonial ayahuasca use in a group (N = 15) of primarily female MENA immigrants and refugees and to provide further insight into the patterns and outcomes surrounding that use. The study sought to assess self-reported changes in physical and mental health, well-being, and psychological functioning, examine relationships between aspects of individual mindset (e.g., psychedelic preparedness) prior to ayahuasca use and observed outcomes during (e.g., subjective drug effects) and afterwards (i.e., persisting effects), characterize risks and negative experiences, and describe trauma exposure and personal history.
Results/Outcomes
Our findings revealed ceremonial use of ayahuasca is associated with significant improvements in mental health, well-being, and psychological functioning, including reductions in depression, anxiety, and shame, and increases in cognitive reappraisal and self-compassion. Most participants reported no lasting adverse effects and experienced notable positive behavioral changes persisting months after ingestion.
Conclusion/Interpretation
While preliminary, results suggest naturalistic ayahuasca use might hold therapeutic potential for MENA populations exposed to trauma prior to and during the process of migration.
Research Summary of 'Long-term benefits to psychological health and well-being after ceremonial use of Ayahuasca in Middle Eastern and North African immigrants and refugees'
βBlossom's Take
Introduction
Lowe and colleagues frame the study around the high burden of cumulative trauma, psychological distress, and barriers to care experienced by Middle Eastern and North African (MENA) immigrants and refugees. They note that although ayahuasca has been associated in earlier research with improvements in mood, wellbeing, trauma-related symptoms, and self-compassion, there is very limited longitudinal evidence on naturalistic ceremonial use in MENA populations. The paper also situates ayahuasca within a broader discussion of psychedelic-assisted healing and the potential relevance of ceremonial settings, while emphasising that public-health evidence for this type of use remains limited. The study aimed to prospectively assess changes in mental health, wellbeing, physical health, and psychological functioning before and after ceremonial ayahuasca use in a small group of primarily female MENA immigrants and refugees. The researchers also sought to examine whether pre-session mindset factors such as absorption, preparedness, and willingness to surrender were associated with acute psychedelic effects, to characterise negative effects and risks, and to describe participants’ trauma histories and personal backgrounds. In effect, the paper is presented as an exploratory longitudinal survey of naturalistic ceremonial use in an understudied population.
Methods
This was a prospective, naturalistic online survey study of adults of Middle Eastern or North African origin who were planning to take ayahuasca outside a clinical research setting. Participants were English-speaking, aged 18 years or older, and excluded if they had experienced a traumatic brain injury. Recruitment was independent of the researchers and occurred through the ceremony organiser. All participants attended the same five-day retreat, which included two consecutive days of ayahuasca ingestion in a group ceremony, along with preparatory activities such as yoga, meditation, breathwork, a sound bath, smudging, and a ritual honouring Pachamama. Integration sessions followed each ceremony and were repeated the next morning. The study used six sequential web-based surveys delivered through Qualtrics XM: an informed consent and demographics survey; a baseline survey completed two weeks before the ceremony; a pre-session survey completed on the day of the ceremony; a post-session survey completed 1 to 3 days afterwards; and follow-up surveys at 2 to 4 weeks and 3 to 4 months. Responses were collected between July and November 2022. Longitudinal outcomes included modified Beck Depression Inventory II (BDI-II) scores for depressed mood, Short State-Trait Anxiety Inventory (STAI) scores for state and trait anxiety, and secondary measures of emotion regulation, self-compassion, shame, cognitive flexibility, physical health, spiritual well-being, burnout, and personality. Pre-session measures also assessed absorption, psychedelic preparedness, surrender, childhood adversity, and PTSD screening. Ayahuasca dose was self-reported in ounces, with approximate categories described as small, medium, or large; no chemical analysis of the brew was performed. Outcomes after the ceremony included mystical experiences, challenging experiences, awe, emotional breakthrough, psychological insight, communitas, and later ratings of meaningfulness, insightfulness, spiritual significance, and behavioural change. The researchers analysed longitudinal measures using Bayesian paired-samples t-tests, with confirmatory classical t-tests when Bayes factors met a prespecified threshold, and also used linear mixed models for overall significance testing. Associations between pre-session variables and acute or longer-term outcomes were examined with Pearson correlations. Measures completed by fewer than 60% of participants at a time point were excluded from analysis.
Results
Fifteen participants provided informed consent. Survey completion ranged from 14 to 15 participants across time points. The mean age was 30.1 years, most participants were female, most lived in the United States, and most held at least a bachelor’s degree. Participants were largely Arab, Middle Eastern, or North African, and all spoke Arabic and English. Most identified as immigrants or refugees, and most reported prior trauma exposure, previous mental health diagnoses, and prior psychedelic experience, although most had not previously used ayahuasca. Common traumas included sexual assault, child abuse, physical assault, serious accidents, natural disasters, and life-threatening illness; many participants linked these to threats of death, serious injury, or sexual violence. Before the ceremony, participants commonly reported self-exploration, mental health, and therapy-related intentions. Most reported good sleep, no alcohol or other drug use immediately beforehand, and no physical ailments on the day of the ceremony. The average dose was medium-to-large on both ceremonial days, and more than half reported taking more than one dose per day. The ceremony was held in a darkened indoor room with a ceremonial guide, helpers, a therapist, and a translator present. Most participants reported that both the guide and the ceremony had a significant positive impact on their experience. For primary outcomes, depression decreased substantially from baseline to 2 to 4 weeks after the ceremony. Mean modified BDI-II scores fell from 19.0 at baseline to 6.0 at 2 to 4 weeks, and the Bayesian analysis provided substantial evidence for improvement (BF10 = 21.72); the paired t-test was also significant with a large effect size. Anxiety showed a similar short-term improvement: state anxiety decreased from 45.9 to 33.6, with substantial Bayesian evidence (BF10 = 7.07). However, neither depression nor anxiety showed clear evidence of lasting change at 3 to 4 months, and scores at 2 to 4 weeks versus 3 to 4 months also did not show convincing change. Among secondary outcomes, cognitive reappraisal increased modestly at 2 to 4 weeks, with weak Bayesian evidence and a significant paired t-test. Self-compassion increased at both 2 to 4 weeks and 3 to 4 months, with significant paired t-tests at both follow-ups and medium effect sizes. Shame decreased over time, with weak evidence for a short-term decrease and substantial evidence for a longer-term decrease reported in the text. By contrast, there was no evidence of longitudinal change in spiritual well-being, cognitive flexibility, physical health, or personality. The Copenhagen Burnout Inventory was not analysed because completion rates were too low. Acute psychedelic effects were generally positive. The mean Mystical Experience Questionnaire score was 0.75, and 60% met the study’s criterion for a complete mystical experience. Mean scores for emotional breakthrough, psychological insight, awe, and communitas were also reported as high. Pre-session preparedness and mindset measures were related to several acute outcomes: mystical experience scores were associated with Psychedelic Predictor Scale set and setting scores and with Tellegen Absorption Scale scores; psychological insight was associated with Psychedelic Predictor Scale set and State of Surrender; awe was associated with Psychedelic Predictor Scale set; and communitas was associated with Psychedelic Predictor Scale setting. State of Surrender was not significantly associated with mystical experience in the reported analysis. Changes in depression and anxiety were linked to certain acute effects. Communitas was significantly associated with later change in depression at 3 to 4 months, although the authors note that this would not survive correction for multiple comparisons. Awe was strongly associated with reductions in both state and trait anxiety at 2 to 4 weeks. Challenging Experience Questionnaire scores were low. Most participants rated the overall experience as positive or extremely positive. At follow-up, most participants still described the ceremony as among the top 10 most meaningful, spiritually meaningful, and psychologically insightful experiences of their lives, although these proportions were lower by 3 to 4 months than at 2 to 4 weeks. Many also rated it among their most psychologically challenging experiences. Behaviourally, most participants reported positive changes, particularly improved relationships, better diet or nutrition, improved work or career life, increased exercise, and reduced alcohol or drug use. Most participants described the experience as beneficial, and nearly all reported that it had led to positive and desirable changes in their wellbeing or life satisfaction. Adverse effects were reported but were mostly short-lived. During and shortly after the ceremonies, some participants reported nausea, vomiting, lack of appetite, fatigue, restlessness, headaches, and physical pain; a minority reported persisting lack of appetite or fatigue after 24 hours. No participant sought medical care, though some sought psychological support from the therapist, helpers, or other participants. At 2 to 4 weeks, a minority reported confusion, disorientation, hallucinations, mood fluctuations, fear, anger, or headaches; at 3 to 4 months, persisting negatives included loneliness, depressive thoughts, lowered motivation, and mood fluctuations. Most participants reported no persisting negative effects at either follow-up.
Discussion
The authors interpret the findings as preliminary evidence that ceremonial ayahuasca use was associated with improvements in mental health, wellbeing, and psychological functioning in a group of primarily female MENA immigrants and refugees. They emphasise short-term reductions in depression and anxiety, alongside increases in self-compassion and cognitive reappraisal, and they note that many participants also reported durable positive behavioural changes. In their view, the low rate of lasting adverse effects suggests that ceremonial use in a monitored setting may represent a relatively low safety risk for this population. The paper places these findings in the context of earlier research showing that ayahuasca and other classic psychedelics may reduce depression and anxiety and may enhance self-compassion and emotion regulation. The authors also argue that the high prevalence of trauma in the sample makes the observed changes particularly relevant, because trauma processing and reconceptualisation may be an important pathway to improved wellbeing in migrants and refugees. They suggest that ceremonial ayahuasca could have therapeutic potential for MENA populations exposed to trauma before, during, and after migration. The authors highlight several potential mechanisms. They argue that pre-session mindset and preparedness mattered: Psychedelic Predictor Scale scores, absorption, and surrender were related to acute mystical, insight, and awe-related effects. They further propose that communitas, or a sense of togetherness and shared humanity, may help explain changes in depression, while awe may be linked to reductions in anxiety. They also present self-compassion and shame as plausible psychological pathways through which ayahuasca might influence mood and resilience. Limitations are emphasised. The sample was very small and relatively homogeneous, which limits generalisability. Data were collected online rather than in person, so responses could not be verified and may have been affected by response bias. The study also lacked an experimental control group, making it impossible to rule out alternative explanations for change. The authors therefore describe the findings as preliminary and call for further research in controlled settings and in broader, less homogeneous samples. They also note that additional studies are needed to clarify the durability of antidepressant and anxiolytic effects and to determine whether repeated use is needed to sustain benefits.
Conclusion
The authors conclude that ceremonial ayahuasca use in this small group of MENA immigrants and refugees was associated with significant improvements in mental health, wellbeing, and psychological functioning, together with mostly positive behavioural changes and few lasting adverse effects. They state that these preliminary findings suggest naturalistic ayahuasca use may have therapeutic potential for MENA populations affected by migration-related trauma.
View full paper sections
STUDY DESIGN
This prospective, naturalistic survey study enrolled mostly female participants of Middle Eastern or North African (MENA) origin identifying as an immigrant, refugee, or nonimmigrant with foreign-born parents. Participants included English-speaking adults aged 18 years or older planning to take ayahuasca outside clinical research settings in a group-based ceremony. Recruitment took place independently through an organizer of the ceremony not affiliated with the study. All participants attended the same retreat where the ceremony took place over five days, including two consecutive days of ayahuasca ingestion. On day one, arrival and introductions took place, followed by yoga and meditation sessions on day two. On day three, the day of the first ceremony, participants took part in breathwork and a sound bath. Immediately prior to the ceremony, participants reported smudging (ceremonial use of sage to clear out negative/stake energies), breathwork exercises, and a ritual honoring of "Pachamama" (Mother Earth). Participants reported ayahuasca was administered in a group setting over two consecutive days by a ceremonial guide at approximately 7:00 pm each day. Integration sessions immediately followed each ceremony and took place again in the morning following the ceremony and prior to departure Participants were provided with detailed instructions on clothing and materials allowed at the ceremony, and dietary and spiritual suggestions included a regimented diet beginning up to 14 days before the ceremony with a list of supplements and prescription medicines that can have contraindications with ayahuasca (See Supplementary Materials). The study design was adapted and modified from Nayak and colleagues, consisting of six sequential web-based surveys assessing variables such as demographics, lifestyle, mindset, and personality traits, as well as characteristics of the experience itself such as dosage, ingestion method, intention, and setting, that could influence long-term effects and outcomes. Longitudinal measures were assessed before and after the ayahuasca sessions and were administered through Qualtrics XM secure online platform. The study was approved by an Institutional Review Board at the Western Institutional Review Board Copernicus Group (WCG IRB). Following an initial informed consent and demographics survey, participants completed 5 surveys with timing relative to the reference ayahuasca experience: 2 weeks before, same day prior to the ceremony, 1 to 3 days after, 2-4 weeks after, and 3-4 months after. Responses were collected from July 9, 2022, to November 29, 2022. In each of the 5 surveys, several openended questions were used to assess participants' experiences throughout the duration of the study, and these qualitative results will be analyzed and reported in a companion study.
DOSING
Ayahuasca was administered in the form of a brew containing leaves of Psychotria Viridis (the source of DMT) and the ayahuasca vine, Banisteriopsis Caapi (the source of enzymatic inhibitors of DMT metabolism). Traditional ayahuasca is variable in appearance, taste, and effects, with considerable variations in alkaloid profiles of ayahuasca from different sources. Due to these variations, approximate dosing information is provided for reference only, and a compound analysis was not performed. Dosage was measured in ounces, with approximately 0.5 ounces (14.8 milliliters) corresponding to "small", 1.0 ounces (29.6 milliliters) corresponding to "medium", and 2.0 ounces (59.2 milliliters) corresponding to "large". No other substances were taken in conjunction with ayahuasca.
SURVEY 1: CONSENT AND DEMOGRAPHIC INFORMATION
Participants were invited to participate in the study if they 1) were at least 18 years old; 2) were able to read and write English fluently; 3) did not experienced a traumatic brain injury (TBI); 4) were planning an ayahuasca experience; and 5) were willing to complete baseline, pre-session, post-session, and follow-up surveys, and share an email address where they received reminders with links to survey assessments. Participants reviewed a waiver of documentation of informed consent explaining the study procedures, confirmed inclusion criteria, and provided basic demographic information including age, gender, race/ethnicity, education, and mental health history. Participants also recorded the purpose and intended date of the planned ayahuasca experience. An email address was provided where subsequent surveys and reminders would be sent. The estimated completion time of Survey 1 was 17 minutes.
SURVEY 2: BASELINE 2 WEEKS PRE-CEREMONY
A series of assessments were administered longitudinally in this survey, at baseline, again in the 2-4 week follow-up, and 3-4 month follow-up surveys. Primary outcomes included a modified 20-item Beck Depression Inventory II (BDI-II) to assess depressed mood (excluding an item about current suicidality due to lack of ability to respond adequately to potential imminent risk)and the validated 20-item Short State-Trait Anxiety Inventory (STAI) assessing state (current) and trait (general) anxiety. Secondary outcomes included the 10item Emotion Regulation Questionnaire (ERQ) assessing cognitive reappraisal (i.e., ability to view emotional stimuli in a variety of ways) and expressive suppression (i.e., tendency to suppress emotional response in a given context) as two dimensions of emotion regulation; the 12-item Self-Compassion Scale -Short form (SCS-SF) was used to assess participants' capacity for self-compassion, or the ability to hold one's feelings of suffering with a sense of warmth, connection, and concerns; the 8-item External and Internal Shame Scale (EISS) was administered to assess external shame, which is shame focused on the experience of the self as seen in a judgmental way by others, and internal shame, which refers to self -focused negative evaluations and feelings about the self; the 12-item Cognitive Flexibility Scale (CFS) assessing self-reported ability to think and behave adaptively; the 4item Patient-Reported Outcomes Measurement Information System Global Health (PROMIS-GH) physical health subscale assessing selfreported physical health; the 12-item Functional Assessment of Chronic Illness Therapy Spiritual Well-Being (FACIT-Sp) assessing spiritual well-being dimensions of faith, meaning, and peace; and the 13-item Copenhagen Burnout Inventory (CBI) assessing personal and work-related burnout and emotional exhaustion. Finally, the 44-item Big Five Inventory (BFI) assessed five major dimensions of personality: Openness, Conscientiousness, Extraversion, Agreeableness, and Neuroticism at 2 weeks prior and 3-4 months after the planned ayahuasca experience. Additionally, some measures were collected only once before the dosing session, including drug use history, the 34-item Tellegen Absorption Scale (TAS) assessing openness to altered states (52), the 14-item Adverse Childhood Experience (ACE) scale (revised) assessing history of childhood physical and emotional abuse or neglect, and the single-item PTSD screener (SIPS). The estimated completion time of Survey 2 was 67 minutes.
SURVEY 3: SAME DAY PRIOR TO CEREMONY
Subjects were asked their planned dosage, intent of the session, outlook regarding the session, as well as physical indications such as current ailments, diet, sleep quality, and substance use. Participants were administered the 14-item Psychedelic Predictor Scale (PPS) to capture thoughts and expectations right before the experience and the willingness to surrender to the experience across two subscales of set and setting. Finally, the 10-item state of surrender (SoS) scale was administered assessing level of psychological surrender or preoccupation before the session, which have previously shown correlations to mystical and challenging subjective effects of psilocybin, respectively. The estimated completion time of Survey 3 was 10 minutes.
SURVEY 4: 1 TO 3 DAYS AFTER CEREMONY
Survey 4 was completed 1-3 days after the second, and final, ayahuasca ceremony. Participants were asked the estimated dosage of ayahuasca they ingested. In addition, participants completed measures of the subjective qualities of the psychedelic experience. The 30-item Mystical Experience Questionnaire (MEQ30) was used to assess the degree of mystical-type (i.e., unitive, positive mood; transcending space or time, ineffable) qualities of the psychedelic experience, with scores ≥ 60% of the maximum score on each of the 4 subscales indicating a "complete mystical experience". The 26-item Challenging Experience Questionnaire (CEQ) assessed a variety of difficult experiences that could arise during the ayahuasca session, comprised of seven factors: grief, fear, death, insanity, isolation, physical distress, and paranoia. The 30-item Awe Experience Scale (AWE-S) was administered to assess the complex emotion of awe and comprised a 6factor structure including altered time perception, self-diminishment, connectedness, perceived vastness, physical sensations, and need for accommodation. The 6-item Emotional Breakthrough Inventory (EBI) was used as a measure of emotional release/breakthrough experienced during an acute psychedelic state. The 6-item Psychological Insight Scale (PIS) was used to assess psychological insight and accompanied behavioral changes after a psychedelic experience. An adapted 8-item version of the Communitas Scale (CS) was used to assess acute relational experiences of perceived togetherness and shared humanity to investigate psychosocial mechanisms pertinent to psychedelic ceremonies and retreats. The estimated completion time of Survey 4 was 35 minutes.
SURVEYS 5 AND 6: FOLLOW-UPS AT 2-4 WEEKS AND 3-4 MONTHS POST-CEREMONY
In surveys 5 and 6, completed approximately 2-4 weeks and 3-4 months after the ayahuasca ceremony, respectively, participants were asked to rate the meaningfulness, insightfulness, and spiritual significance of the experience. Items asked: "How personally meaningful/psychologically insightful/spiritually significant was your ayahuasca experience and your contemplation of that experience?" Responses ranged across eight options from "No more than routine, everyday experiences" to "The single most meaningful/insightful/spiritually significant experience of my life." As noted above, the BFI was re-administered in survey 6 at 3-4 months after the ayahuasca experience. Otherwise, all longitudinal measures (i.e., BDI-II, STAI, ERQ, CFS, PROMIS-GH, FACIT-Sp, CBI) were re-administered in these surveys. The estimated completion time of Survey 5 and 6 was 48 minutes.
DATA ANALYSIS
Descriptive statistics including means, SD and ranges were performed for demographic variables. Measures were included in the analysis if they were completed by ≥ 60% of participants at each timepoint. For longitudinal measures, Bayesian inference was used to compare differences across time points. Bayes factors (BF) indicate the relative strength of evidence for two theories (e.g.,. The Bayes factor B comparing an alternative hypothesis to the null hypothesis means that the data are B times more likely under the alternative than under the null. Following Jeffreys et al., a conventional cut-off for substantial evidence to support the alternate hypothesis includes a Bayes factor greater than 3. Conversely, anything between 1/3 and 3 is considered weak or "anecdotal" evidence. However, to account for adjustments required to control type I error rates, a suggested cut-off score was set at 2. Comparisons for longitudinal outcomes (i.e., BDI-II, STAI, ERQ, CFS, PROMIS-GH, FACIT-Sp, CBI) were performed using a Bayesian paired samples t-test (BF 10 ) using JASP statistical software (65) for each variable pair across time (baseline versus 2-4 weeks; baseline versus 3-4 months; 2-4 weeks versus 3-4 months). For any comparisons equal to or greater than the suggested cutoff score of 2, standard paired-samples t-test were performed for confirmatory analyses, and effect sizes were reported using Cohen's d and 95% confidence intervals. In addition to Bayesian inference, linear mixed models were included to assess overall significance of primary and secondary outcomes (see Supplementary Materials). To assess what aspects of the psychedelic experience were associated with long-term changes on the primary outcomes, change scores on the BDI, STAI-T and STAI-S were calculated by subtracting baseline scores from each of the endpoints (2-4 weeks and 3-4 months). Subsequently, Pearson correlations were computed between the resulting change scores and each of the five post-session measures MEQ, CEQ, EBI, AWE-S, COMS, resulting in 10 comparisons per outcome variable: five for the 2-4 week and five for the 3-4 month endpoint. A priori correlations (Pearson's r) assessed associations between several measures assessed prior to the ingestion of ayahuasca, including absorption (TAS), openness to surrendering to the experience (SoS), and set and setting (PPS) with outcomes of mystical experiences (MEQ30), emotional breakthrough (EBI), psychological insight (PIS) and awe (AWE-S). Baseline adverse childhood experiences (ACE) were also correlated with post-session challenging experiences (CEQ).
PARTICIPANT DEMOGRAPHICS
Fifteen participants provided informed consent for the study (Survey 1). Sample sizes for each of the following surveys were N = 14 (Survey 2; weeks pre-session), N = 15 (Survey 3; same day prior pre-session), N = 15 (Survey 4; 1-3 days post-session), N = 14 (Survey 5; 2-4 weeks post-session), and N = 15 (Survey 6; 2-3 months post-session). Mean age (SD) was 30.1 years (7.2). Most participants were female (n = 11; 73.3%), residing in the United States (n = 11; 73.3%), held a bachelor's level or higher degree (n = 11; 73.3%), and classified themselves as religious (n = 9; 60.0%). Participants identified as an immigrant or refugee (n = 10; 66.7%), nonimmigrant with foreign-born parents (n = 3; 20%), or nonimmigrant visitor primarily residing in the country of their birth (n = 2; 13.3%). Participants identified as Arab, Middle Eastern, or North African (n = 12; 80.0%) and Mixed Race (n = 3; 20.0%), and all participants spoke Arabic and English.
PERSONAL HISTORY
In Survey 2, while most participants (n = 9; 60%) reported previously taking a dose of a classic psychedelic (e.g., psilocybin mushrooms, psilocybin, LSD, ayahuasca, mescaline, DMT, etc.) that produced moderate to strong psychoactive effects, most participants had no experience of using ayahuasca prior to enrolling in the study (n = 12; 80.0%). The most commonly reported prior psychedelic use was psilocybin (n = 8; 53.3%), followed by LSD (n = 6; 40.0%). Most participants (n = 12; 80.0%) had been previously diagnosed or struggled with a mental health condition, including an anxiety disorder (n = 10; 66.7%), mood disorder (n = 8; 53.3%), eating disorder (n = 4; 26.7%), personality disorder (n = 1; 6.7%), or substance-related disorder (n = 1; 6.7%).
EXPERIENCES OF TRAUMA
In Survey 2, using the single-item PTSD screener (SIPS), 50% of the sample (n = 7) reported that they had been recently bothered by an experience that caused them to believe they would be injured or killed. Most participants (n = 11; 78.6%) reported that they had experienced, witnessed, or had been repeatedly confronted with a traumatic experience. Forms of trauma experienced by participants included sexual assault (n = 6; 42.86%), child abuse (n = 6; 42.86%), physical assault (n = 4; 28.56%), serious accident (n = 2; 14.29%), natural disaster (n = 1; 7.14%), and life-threatening illness (n = 1; 7.14%). Some participants described their experience as other trauma (n = 5; 35.71%), including descriptions such as, "Leaving my home country for the last time where I knew there was a threat to me and my partner". Many participants (n = 7; 50.0%) reported this experience involved actual or threatened death, serious injury, or sexual violence.
INTENTION
On the day of the ayahuasca ceremony immediately prior to the experience (Survey 3), participants characterized the purpose for the ayahuasca ceremony as (non-exclusively) self-exploration (n = 13; 86.7%), creativity (n = 9; 60.0%), mental health (n = 8; 53.3%), physical health (n = 5; 33.3%), therapy (n = 4; 26.7%), productivity (n = 4; 26.7%), and recreation (n = 2; 13.3%). All respondents (n = 15; 100.0%) reported setting a specific intention for the experience. For example, one participant stated, "I want to heal from the abuse I endured to be able to be the best version of myself," and another wrote, "I want to get back in touch with my true self. I want to be brave to become my authentic self publicly."
PHYSICAL INDICATIONS, DIET, AND EXERCISE
In the period leading up to the ceremony (Survey 2), most participants reported regular (≥ once/per week) physical exercise (n = 10; 71.4%), and three or more servings of fruit and vegetables each day (n = 8; 57.1%). On the day of the ceremony (Survey 3), most participants (n = 13; 86.7%) reported no physical ailments. In the 24 hours prior to the experience, mean (SD) reported restful sleep was 7.0 (1.5) hours, all participants reported no alcohol consumption or use of caffeine, cannabis, selective serotonin reuptake inhibitors (SSRIs), benzodiazepine, prescription or other stimulants, nootropic, opioid, or other psychedelic, and one participant reported use of nicotine (n = 1; 6.7%). In the 48 hours prior to the experience, many participants (n = 7; 46.7%) reported no consumption of gluten, dairy, red meat, white meat, seafood, or processed sugars, and some reported consumption of gluten (n = 4; 26.7%), dairy (n = 2; 13.3%), white meat (n = 2; 13.3%), and seafood (n = 1; 6.7%).
DOSAGE
The majority (n = 8; 53.3%) of participants reported taking more than one dose on each day of the ceremony. No other substances were taken in conjunction with ayahuasca. On day one, the mean (SD) dosage was 1.41 (0.73) ounces or 41.7 (21.6) milliliters, corresponding to a medium-to-large dose, and on day two, the mean (SD) dosage was 1.31 (0.53) ounces or, 38.7 (15.7) milliliters corresponding to a medium-to-large dose.
SETTING
Participants attended an ayahuasca ceremony as part of a fiveday retreat. The ceremony took place indoors in a darkened room used as a sensory limiting tool. In addition to the ceremonial guide, three male helpers, three female helpers, a female licensed therapist, and a translator attended the ceremony. The ceremony guide reported receiving over a decade of training from a shaman in the Amazonian regions of Peru, and several years independently leading ayahuasca ceremonies. In the post-session survey completed 1 to 3 days post-ceremony (Survey 4; N = 15), participants reported live instrumentals, live vocals, and shamanic or ritualistic music were performed by the ceremony guide. In a Likert scale rating how important the ceremony and guide were in shaping their experience, most of the participants (n = 13; 86.7%) reported that both the guide and ceremony had a significant positive impact. In the morning immediately following both ayahuasca sessions, participants performed group integration practices and were also offered independent one-on-one sessions with a licensed therapist.
MOOD
In Survey 2 (2-4 Weeks Pre-Session), most participants (n = 13; 86.7%) indicated they had previously struggled with depressed mood. Modified BDI-II mean (SD) total scores of these participants were 19.0 (12.2) for survey 2, with 71.4% (n = 10) of respondents meeting criteria for some form of depression (mild mood disturbance). For Surveys 5 and 6, modified BDI-II mean (SD) total scores were 6.0 (6.0) and 12.2 (11.7), respectively, with 7.7% of respondents (n = 1) meeting depression criteria for Survey 5, and 38.5% (n = 5) meeting depression criteria for Survey 6. Bayesian analysis of BDI scores showed substantial evidence for a decrease in depression from baseline to 2-4 weeks post-session (BF 10 = 21.72), but not from baseline to 3-4 months post-session (BF 10 = 0.86), or from 2-4 weeks to 3-4 months postsession (BF 10 = 1.45). A paired-sample t-test [Cohen's d; 95% CI] confirmed significantly decreased depression from baseline to 2-4 weeks post-session (p = 0.002; t = 4.11; df = 10) with a large effect size [1.24; 0.43, 2.02] (Figure).
ANXIETY
In Survey 2 (2-4 Weeks Pre-Session), most participants (n = 13; 86.7%) indicated they had previously struggled with anxiety. Short STAI state and trait anxiety mean (SD) total scores were 45.9 (12.0) and 45.9 (8.8), respectively. For Survey 2, 69.2% (n = 9) of respondents met criteria for high-risk state anxiety, and 76.9% (n = 10) met criteria for high-risk trait anxiety. For Survey 5, short STAI state and trait anxiety mean (SD) total scores were 33.6 (9.9) and 38.1 (10.2), respectively. For Survey 5, 22.2% (n = 2) of respondents met criteria for high-risk state anxiety, and 22.2% (n = 2) met criteria for high-risk trait anxiety. For Survey 6, short STAI state and trait anxiety mean (SD) total scores were 37.0 (11.7) and 39.6 (10.3), respectively. For Survey 6, 36.4% (n = 4) of respondents met criteria for high-risk state anxiety, and 45.5% (n = 5) met criteria for high-risk trait anxiety. Bayesian analysis of STAI scores showed substantial evidence for a decrease in state anxiety from baseline to 2-4 weeks post-session (BF 10 = 7.07), but not from baseline to 3-4 months post-session (BF 10 = 0.68), or from
SECONDARY OUTCOMES OF LONGITUDINAL MEASURES EMOTION REGULATION
Mean (SD) ERQ cognitive reappraisal and expressive suppression scores on Survey 2 were 4.5 (1.1) and 3.7 (0.8), respectively (Figure). For Survey 5, ERQ cognitive reappraisal and expressive suppression scores were 5.2 (1.3) and 4.2 (1.2), respectively. For Survey 6, ERQ cognitive reappraisal and expressive suppression scores were 5.2 (1.3) and 3.6 (1.6), respectively. Bayesian analysis of ERQ scores showed weak evidence for an increase in cognitive reappraisal from baseline to 2-4 weeks post-session (BF 10 = 2.02), but not from baseline to 3-4 months post-session (BF 10 = 1.34), or from 2-4 weeks to 3-4 months post-session (BF 10 = 0.30). A paired-sample t-test [Cohen's d; 95% CI] confirmed significantly increased cognitive reappraisal from baseline to 2-4 weeks post-session (p = 0.037; t = -2.34; df = 12) with a medium effect size [-0.65; 1.24, -0.04]. Bayesian analysis revealed limited to no evidence for differences at any timepoint for expressive suppression.
SELF-COMPASSION
The mean (SD) SCS-SF score on Survey 2 was 3.2 (0.6), indicating a moderate level of self-compassion. Mean (SD) scores for Survey 5 and Survey 6 were 3.5 (0.7) and 3.6 (0.7), respectively, indicating a high level of self-compassion. Bayesian analysis of SCS-SF scores showed weak evidence for an increase in self-compassion from baseline to 2-4 weeks post-session (BF 10 = 2.40), and from baseline to 3-4 months post-session (BF 10 = 2.28). No evidence of change was found from 2-4 weeks to 3-4 months post-session (BF 10 = 0.28). Paired-samples t-tests [Cohen's d; 95% CI] of SCS-SF scores confirmed significantly increased self-compassion from baseline to 2-4 weeks post-session (p = 0.030; t = -2.46; df = 12) with a medium effect size [-0.68; -1.28, -0.06], and from baseline to 3-4 months (p = 0.031; t = -2.42; df = 13) with a medium effect size [-0.65; -1.22, -0.06].
SHAME
Mean (SD) total EISS scores on Surveys 2, 5, and 6 were 13.4 (5.9), 10.2 (5.5), and 9.4 (4.6), respectively. Bayesian analysis of EISS scores showed weak evidence for a decrease in shame from baseline to 2-4 weeks post-session (BF 10 = 2.14), and substantial evidence for a decrease in shame from baseline to 3-4 months post-session
NON-SIGNIFICANT AND EXCLUDED SECONDARY OUTCOMES
No evidence for longitudinal changes were found across timepoints for the FACIT-Sp (all ps ≥ 0.097), CFS (all ps ≥ 0.222), PROMIS-GH (all ps ≥ 0.297), and BFI (all ps ≥ 0.095). The CBI was excluded from analysis due to insufficient completion rates (≤ 60%).
CHANGES IN DEPRESSION
Pearson correlations between change scores on the BDI from baseline to the 2-4 week and 3-4 months endpoints versus each of the five post-session measures of acute psychedelic effects were calculated. Among the 10 correlations, the only significant association was found between communitas scores and depression changes between baseline and the follow-up endpoint at 3-4 months (r = .57, p = .04, Figure). However, this association would not have survived correction for multiple comparisons.
CHANGES IN ANXIETY
Among the five measures of acute subjective effects, only awe was significantly associated with changes in anxiety, specifically with state (r = -.86, p = .003) and trait anxiety (r = -.8, p = .009) at the 2-4 week endpoint.
CHALLENGING EXPERIENCES
The mean (SD) total Challenging Experience Questionnaire (CEQ) score was 0.38 (0.26) in Survey 4. CEQ scores were not significantly
MYSTICAL EXPERIENCES
The mean (SD) total Mystical Experience Questionnaire (MEQ30) score in Survey 4 was 0.75 (0.15), with 9 (60.0%) meeting a priori criteria for a "complete mystical experience." MEQ30 scores were significantly associated (Pearson's r) with presession Psychedelic Predictor Scale (PPS) scores of Set (r = 0.627, p = 0.012) and Setting (r = 0.607, p = 0.016) in Survey 3 and with presession Tellegen Absorption Scale (TAS) scores (r = 0.576, p = 0.031) in Survey 2. MEQ30 scores were not significantly associated with State of Surrender (SoS) scores in Survey 2 (r = 0.490, p = 0.064).
EMOTIONAL BREAKTHROUGH
The mean (SD) total Emotional Breakthrough Inventory (EBI) score was 0.65 (0.
PSYCHOLOGICAL INSIGHT
The mean (SD) total Psychological Insight Scale (PIS) score was 0.72 (0.25) Survey 4. PIS scores in Survey 4 were significantly associated (Pearson's r) with pre-session PPS scores of Set (r = 0.650, p = 0.009) but not Setting (r = 0.305, p = 0.268) in Survey 3, and were significantly associated with SoS scores in Survey 2 (r = 0.702, p = 0.004). PIS scores were not significantly associated (Pearson's r) with pre-session TAS scores (r = 0.342, p = 0.231) in Survey 2.
AWE
The mean (SD) total Awe Experience Scale (AWE-s) score was 0.77 (0.88) in Survey 4. AWE-S scores were significantly associated (Pearson's r) with pre-session PPS scores of Set (r = 0.739, p = 0.002)
COMMUNITAS
The mean (SD) total Communitas Scale (CS) score was 0.91 (0.11) in Survey 4. CS scores were significantly associated with presession PPS scores of Setting (r = 0.540, p = 0.038), but not Set. CS scores were not significantly associated with either TAS or SoS scores.
RATING THE OVERALL EXPERIENCE
In Survey 4 (1-3 Days Post-session), on a 7-point Likert scale rating the experience ranging from "Extremely negative" to "Extremely positive", most participants rated the experience as positive (n = 14; 93.3%), and the majority rated the experience as "Extremely positive" (n = 12; 80.0%). No participants rated the experience as negative, and one participant (n = 1; 7%) rated the experience as "Neither positive nor negative".
ATTRIBUTIONS OF MEANING, SPIRITUAL SIGNIFICANCE, INSIGHT, AND PSYCHOLOGICAL CHALLENGE
In Survey 5 (2-4 weeks post-session), most participants considered the ceremony to be among the top 10 most personally meaningful (n = 13; 92.9%), top 10 most spiritually meaningful (n = 12; 85.7%), and top 10 most psychologically insightful (n = 12; 85.7%) experiences of their lives (Table). Many respondents (n = 6; 42.9%) considered the ceremony as among the top 10 most psychologically challenging experiences of their life. In Survey 6 (3-4 Months post-session), most participants still considered the ceremony to be among the top 10 most personally meaningful (n = 9; 60.0%), top 10 most spiritually meaningful (n = 9; 60.0%), and top 10 most psychologically insightful (n = 9; 60.0%) experiences of their lives. Many respondents (n = 7; 46.7%) reported that the ceremony was among the top 10 most psychologically challenging experiences of their lives. Self-reported behavioral changes after ceremonial use of ayahuasca 85.7% and 86.7% of participants reported notable behavioral changes at 2-4 weeks and 3-4 months after their ayahuasca experience, respectively (Table). The most commonly reported behavioral changes were improved relationships with others (n = 9; 64.3% at 2-4 weeks, and n = 7; 46.7% at 3-4 months), improved diet/ nutrition (n = 8; 57.1% at 2-4 weeks, and n = 7; 46.7% at 3-4 months), improvements in career/work life (n = 8; 57.1% at 2-4 weeks, and Acute psychedelic effects of communitas and awe are significantly associated with longitudinal changes in depression (A) state (B) and trait anxiety (C). n= 4; 26.7% at 3-4 months), increased physical activity/exercise (n = 5; 35.7% at 2-4 weeks, and n = 7; 46.7% at 3-4 months), reduced or stopped using other drugs (n = 6; 42.9% at 2-4 weeks, and n = 2; 13.3% at 3-4 months), and reduced craving or use of alcohol (n = 3; 21.4% at 2-4 weeks, and n = 5; 33.3% at 3-4 months). Almost all respondents characterized their experience using ayahuasca as beneficial 2-4 weeks (92.6%), and all at 3-4 months (100.0%) afterwards. When participants were asked if they believed the ayahuasca experience and their contemplation of that experience led to long-term and persisting changes in their current sense of personal well-being or life satisfaction, all participants considered the change as positive and desirable at 2-4 weeks, and 93.3% of considered the change as positive and desirable at 3-4 months. One participant (6.7%) reported negative and undesirable changes at 3-4 months.
SYMPTOMS & ADVERSE EFFECTS
Participants reported several adverse events (Table) during and after the ayahuasca ceremony. While most adverse events did not persist in the 24 hours following the ceremony, respondents reported some persisting symptoms including lack of appetite (n = 6; 40.0%) and fatigue (n = 4; 26.7%). Some participants (n = 4; 26.7%) experienced physical pain during the ceremony, with a mean (SD) pain rating of 6.75 (0.50) on a scale out of 10, lasting a mean (SD) duration of 4.0 (1.6) hours. Descriptions of where pain sensation occurred included abdomen (stomach area) (n = 3; 20.0%), chest area (n = 2; 13.3%), anal/perineal/genital (n = 2; 13.3%), lower back/spine (n = 1; 6.7%) and shoulder (n = 1; 6.7%). No respondents reported seeking medical care during the experience, and many (n = 6; 40%) reported seeking psychological care. Descriptions of these events included speaking with the therapist, helpers, and other participants on site (e.g., "I talked to some of the helpers and participants and that helped me to integrate and feel less anxious or angry."). Regarding persisting negative effects, most participants reported no persisting negative effects at each longitudinal follow up (Survey 5 & 6; n = 9; 60.0%). In the first longitudinal follow up (Survey 5; 2-4 Weeks Post-Session), persisting negatives effects included confusion (n = 3; 21.4%), disorientation (n = 1; 7.1%), persisting hallucinations (n = 1; 7.1%), mood fluctuations (n = 1; 7.1%), fear (n = 1; 7.1%), anger (n = 1; 7.1%), and headaches (n = 1; 7.1%). In the second longitudinal follow up (Survey 6; 3-4 Months), persisting negatives effects included loneliness (n = 3; 20.0%), depressive notions (n = 2; 13.3%), lowered motivation (n = 2; 13.3%), and mood fluctuations (n = 1; 6.7%).
DISCUSSION
This study presents a prospective, longitudinal assessment of psychological health and wellbeing after ceremonial use of ayahuasca in a group of primarily female immigrants and refugees of Middle East and North Africa (MENA) descent. We report significant improvements in mental health, well-being, and psychological functioning, including reductions in depression, anxiety, and shame, and increases in cognitive reappraisal and self-compassion. Additionally, most participants reported positive behavioral changes which persisted for months following the ceremony, such as improved relationships, diet/nutrition, career/ work life, increased physical activity/exercise, and reduced use or craving of alcohol and other drugs. Only a small minority of participants experienced lasting adverse effects such as confusion and mood fluctuations, suggesting monitored, ceremonial use of ayahuasca may represent a relatively low safety risk. Although preliminary, our findings suggest ceremonial ayahuasca use may hold broad therapeutic potential for MENA populations exposed to trauma prior to and during the process of migration. Worsened diet/nutrition 0 (0.0) 1 (6.7) Increased physical activity/exercise 5 ( Decreased physical activity/exercise 1 ( Improved relationships with others 9 ( Worsened relationships with others 0 (0.0) 0 (0.0) Improvements in career/work life 8 (57.1) 4 (26.7) Worsening of career/work life 0 (0.0) 1 (6.7) None of these 2 (14.3) 2 (13.3) 1 Ratings provided on the following 8-point scale: No more than routine, everyday personally meaningful/spiritually significant/psychologically insightful/challenging experiences=1; Similar to experiences that occur on average once or more a week=2; Similar to experiences that occur on average once a month=3; Similar to experiences that occur on average once a year=4; Similar to experiences that occur on average once every 5 years=5; Among the 10 most personally meaningful/spiritually significant/psychologically insightful/challenging experiences of my life=6; Among the 5 most personally meaningful/spiritually significant/ psychologically insightful/challenging experiences of my life=7; The single most personally meaningful/spiritually significant/psychologically insightful/challenging experience of my life=8.
STRESSOR EXPOSURE AND CONSEQUENCES IN IMMIGRANTS AND REFUGEES OF MENA DESCENT
Approximately 40% of the 60 million individuals displaced worldwide originate from MENA regions. There is a critical failure of international agreements to effectively provide viable solutions to the humanitarian ramifications of mass population movements, especially in vulnerable population groups such as immigrants and refugees, who have struggled to retain the rights, quality of life, and access to health care and educational standards. It has been well documented that accumulated lifetime trauma experience increases the likelihood of developing psychological distress and psychiatric disorders [e.g.,]. Compared with the general population, MENA immigrants and refugees may face increased rates of traumatic experiences, including historical trauma and pervasive institutional discrimination. A primary health risk for immigrants and refugees from the MENA regions stems from mental health disorders, mainly PTSD, depression, and anxiety. Due to limited access to mental health services, these individuals may neglect their conditions and subsequent consequences, often resulting in negative long-term social, psychological, and economic impacts. Consistent with these findings, nearly 80% of participants in the present study reported that they had experienced, witnessed, or had been repeatedly confronted with a traumatic experience, including sexual assault, child abuse, physical assault, serious accident, natural disaster, and life-threatening illness, for example, "Leaving my home country for the last time where I knew there was a threat to me and my partner." Half of the participants reported these experiences involved actual or threatened death, injury, or sexual violence. These experiences can produce profound long-term consequences for mental health and wellbeing. In fact, over 80% of participants indicated that they had been previously diagnosed or struggled with depressed mood or anxiety, and over 70% of participants met the criteria for some form of depression and high-risk anxiety. The therapeutic processes associated with ayahuasca use may be particularly valuable for the cumulative racial-ethnic trauma experiences among immigrants and refugees of MENA descent, including the ability to reconceptualize and process traumatic experiences, which may in turn lead to improvements in mental health and wellbeing.
CEREMONIAL AYAHUASCA USE IS ASSOCIATED WITH BENEFITS TO MENTAL HEALTH
Accumulating evidence from cross-sectional, preclinical, and experimental studies suggest that ayahuasca has both antidepressant and anxiolytic effects. Robust evidence from controlled and open-label trials shows reduced depression scores following the administration of ayahuasca. Similarly, although anxiety studies show mixed results [see], some studies suggest ayahuasca may have therapeutic potential in the treatment of anxiety [e.g.,]. Consistent with these findings, results of the present study found significant reductions in the primary outcome measures of depression and anxiety 2-4 weeks after the ingestion of ayahuasca in a ceremonial setting. While more than two thirds of respondents met criteria for some form of depression and high-risk anxiety prior to the ceremony, only 7.7% and 22.2% of participants met criteria 2-4 weeks after ingestion of ayahuasca, respectively. However, significant reductions in scores of both depression and anxiety did not persist 3-4 months after ingestion. Although these findings suggest the antidepressant and anxiolytic effects of ceremonial ayahuasca use may have a time-limited window similar to observational and clinical trial data of psilocybin-assisted treatment, other evidence supports sustained reductions in depression in clinically depressed patients 1 year after attendance of an ayahuasca ceremony. Further research is needed to examine the long-term efficacy of ayahuasca on mental health in different populations and broader samples, and whether some individuals may benefit from repeated use to sustain the antidepressant and anxiolytic effects of ayahuasca ingestion. Nevertheless, the present results suggest ceremonial use of ayahuasca may hold significant treatment Positive changes to experiences of shame, self-compassion, and emotion regulation Classic psychedelics used with therapeutic intent have been shown to reduce internalized shameand increase selfcompassion. Particularly noteworthy in the present study were findings that ceremonial use of ayahuasca altered longitudinal measures of self-compassion and shame. In a systematic review of empirical literature on the relationship between self-compassion and psychopathology, increased self-compassion was associated with lower levels of mental health symptoms, emphasizing the importance of self-compassion for developing well-being, reducing depression and anxiety, and increasing resilience to stress. Similarly, higher levels of shame are associated with lower satisfaction with mental health and characterized by more negative attitudes towards seeking professional help. In the present study, significant reductions in shame and increases in self-compassion accompanied reductions in depression and anxiety, suggesting potential mechanisms for the improvement of mental health and wellbeing after the ingestion of psychedelic substances. These results are consistent with prior work indicating changes in self-compassion mediate the effects of psychedelic experiences on outcomes of depression and anxiety. In a prospective, longitudinal investigation of naturalistic psilocybin use, cognitive reappraisal, an aspect of emotional regulation defined as the ability to change one's thoughts about emotionally charged stimuli, showed significant increases after psilocybin, while expressive suppression, referring to inhibition of behavioral responses to emotionally charged stimuli, showed no change.. Our findings are consistent with these results, indicating increases in the emotional regulation strategy of cognitive appraisal following ayahuasca use, with no change to expressive suppression. Emotion regulation strategy plays a significant part in the experience and expression of emotions and their effect on physical and mental health. Cognitive reappraisal, which denotes the ability to change one's thoughts about emotionally charged stimuli, showed significant increases after ayahuasca ingestion, while expressive suppression, referring to inhibition of behavioral responses to emotionally charged stimuli, showed no change. Positive cognitive reappraisal strategies are correlated significantly and positively with positive indicators of mental healthand are generally associated with healthier patterns of social and emotional functioning than expressive suppression. Existing literature on positive cognitive reappraisal suggests a moderating role of cognitive reappraisal on the relationship between stressor exposure and psychopathology, presenting positive cognitive reappraisal as a viable candidate for increasing wellbeing and decreasing negative symptomology.
PREDICTING ACUTE PSYCHEDELIC EFFECTS AFTER AYAHUASCA INGESTION
We observed significant associations between several presession-measures and acute post session outcomes occurring immediately after (1-3 days) the ayahuasca experience. Acute experiences of mysticism, emotional breakthrough, psychological insight, and awe were significantly associated with several presession measures, including the Psychedelic Predictor Scale (PPS), which captures thoughts and expectations right before the experience and the willingness to surrender to the experience across two subscales of set and setting (55), the Tellegen Absorption Scale (TAS), which assesses openness to altered states, and the State of Surrender (SoS), which is defined as a readiness to accept whatever was, whether good or bad, without resisting or fighting or struggling. Interestingly, the PPS was associated with all four measures of acute experiences, including mystical experiences, emotional breakthrough, psychological insight, and awe, suggesting it's a strong predictor of multiple acute outcomes of the psychedelic experience. Consistent with prior research, our data suggests that having clear intentions and positive expectations for the psychedelic experience facilitates the occurrence of acute psychedelic experiences which may in turn lead to positive outcomes in measures of depression, anxiety, shame, selfcompassion, and emotional regulation. While a relatively new scale, these results suggest the PPS may be a useful tool to measure psychedelic preparedness and predict outcomes to longitudinal changes in mental health and wellbeing, although further studies are needed to investigate whether these results are generalizable to less homogenous samples and different psychedelic substances, and a specific validation on the PPS is still pending.
LONGITUDINAL CHANGES AND ACUTE PSYCHEDELIC EFFECTS AFTER AYAHUASCA INGESTION
Findings from the current study revealed that changes in measures of depression and anxiety were significantly associated with communitas and awe scores, respectively. Communitas reflects relational experiences of perceived togetherness and shared humanity, and is associated with increases in psychological wellbeing, social connectedness, and other mental health outcomes. Given the shared background and homogeneity of the sample in the present study, perceived togetherness of the participants may have been an important contributing factor for positive outcomes of psychedelic ingestion. Holding safe spaces has been an essential component of community-based harm reduction in the use of psychedelics. A sense of belonging has been associated with decreased symptoms of depression, suggesting an important link between relationship-oriented experiences and depression. Awe, on the other hand, is a complex emotion comprised of an appraisal of vastness and a need for accommodation that has been associated with benefits to mental and physical health. Here, awe was positively associated with decreased symptoms of both state and trait anxiety. Together, we found that longitudinal changes in depression and anxiety may be mediated by acute psychedelic effects related to perceived togetherness and awe, respectively. Consistent with prior work examining longitudinal health outcomes of psilocybin, no changes were found in selfreported physical health following ayahuasca use, suggesting minimal impact of ceremonial ayahuasca use on physical health factors. In contrast to Nayak and colleagues, however, we observed no changes in spiritual well-being, cognitive flexibility, or personality. Differences in the phenomenological experience of ayahuasca and psilocybin may potentially mediate these longitudinal outcomes, but further research in the general population is needed to assess this possibility.
LONGITUDINAL SUBJECTIVE CHANGES AFTER INGESTION OF AYAHUASCA
In the days immediately following the ayahuasca ceremony, nearly all participants rated the overall experience as positive, and most considered the experience as "Extremely Positive". Despite many of the participants reporting that the experience was one of the most psychologically challenging experiences of their life, most considered the experience among the top 10 most personally meaningful, most spiritually meaningful, and most psychologically insightful experiences of their life. The majority of participants reported notable behavioral changes at both longitudinal followups, with the most reported changes being improved relationships with others, improved diet/nutrition, improvements in career/work life, and increased physical activity/exercise. Additionally, many participants reported reduced use or craving of alcohol and other drugs consistent with prior research reporting reduced use of substances such as alcohol, tobacco, and cannabis after ayahuasca use, These findings suggest ceremonial ayahuasca may produce significant positive changes in lifestyle and behavior and hold broad benefits to general wellbeing in MENA individuals.
NEGATIVE EFFECTS
Overall, ayahuasca use is considered to be physiologically and psychologically safe, especially in controlled settings [for a review, see]. Although preliminary, the evidence presented here is consistent with these conclusions. While some participants reported both acute symptoms experienced during and immediately following (<24 hours) the ayahuasca experience, including nausea and/or vomiting, lack of appetite, restlessness, headaches, and physical pain, among others, most of these symptoms resolved in the 24 hours following the experience. It is also important to note that acts of purging, such as vomiting, are considered integral to the therapeutic use of ayahuasca and should not be dismissed as a side effect but rather reconsidered for its potential therapeutic effects. A minority of participants reporting persisting symptoms including lack of appetite and fatigue. However, no respondents reported seeking medical care during the experience, and only some participants reported seeking psychological care during the ceremony, including speaking with a trained therapist, helpers, and other participants on site, highlighting the importance of experienced on-site care for those attending psychedelic ceremonies. Almost all participants reported no persisting negative effects at each longitudinal follow-up, providing preliminary evidence suggesting ayahuasca use within a ceremonial setting attended by experienced facilitators represents a relatively low risk for this specific, less studied (MENA) population.
STUDY LIMITATIONS
The current study findings have several limitations and should be interpreted carefully. Due to the homogeneity of the majority immigrant and refugee female sample of MENA descent, as well as the small sample size of the participant group, findings of the present study should not be generalized to the wider population. Because the data were gathered online and in different settings prior to and after the ceremony, it is not possible to verify participant responses and response bias among this sample may have influenced how participants chose to answer survey questions. Additionally, a further limitation includes a lack of an experimental control group for an adequate comparison. Finally, in contrast to previous results, as such, these results should be treated as preliminary evidence requiring further investigation in controlled settings.
CONCLUSION
For immigrants and refugees of MENA descent, postmigration challenges tied to resettlement in another country pose a significant risk for poor mental health and psychological wellbeing, and these challenges are particularly salient in light of limited access to health care and educational standards. There is a critical need to attend to MENA individuals' experiences of cumulative trauma, particularly as it relates to the process of immigration or refugee resettlement. Our findings revealed ceremonial use of ayahuasca in a group of primarily female immigrants and refugees of MENA descent is associated with significant improvements in mental health, wellbeing, and psychological functioning, including depression, anxiety, shame, emotion regulation strategies of cognitive reappraisal, and self-compassion. Most participants reported no lasting adverse effects and experienced notable positive behavioral changes persisting months after ingestion. While preliminary, these results suggest that naturalistic ayahuasca use may hold therapeutic potential for MENA populations exposed to trauma prior to and during the process of migration.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Populationhumans
- Characteristicsre analysissurvey
- Journal
- Compound
- Topics
- APA Citation
References (29)
Papers cited by this study that are also in Blossom
Kjellgren, A., Eriksson, A., Norlander, T. · Journal of Psychoactive Drugs (2009)
Frecska, E., Bokor, P., Winkelman, M. J. · Frontiers in Pharmacology (2016)
Dos Santos, R. G. · Journal of Psychoactive Drugs (2013)
Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)
Araújo, D. B., Zeifman, R. J., Palhano-Fontes, F. et al. · Frontiers in Pharmacology (2019)
Barbosa, P., Mizumoto, S., Bogenschutz, M. P. et al. · Drug Testing and Analysis (2012)
Smith, W. R., Appelbaum, P. S. · JAMA (2021)
Peill, J. M., Trinci, K. E., Kettner, H. et al. · Journal of Psychopharmacology (2022)
Russ, S. L., Carhart-Harris, R. L., Maruyama, G. et al. · Psychology of Consciousness Theory Research and Practice (2019)
Nayak, S., Jackson, H., Sepeda, N. D. et al. · Frontiers in Psychiatry (2023)
Show all 29 referencesShow fewer
Callaway, J. C., Mckenna, D. J., Grob, C. S. et al. · Journal of Ethnopharmacology (1999)
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)
Kettner, H., Rosas, F. E., Timmermann, C. et al. · Frontiers in Pharmacology (2021)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · brazilian Journal of Psychiatry (2016)
Osório, F. L., Sanches, R. F., Macedo, L. et al. · brazilian Journal of Psychiatry (2015)
Sanches, R. F., Osório, F. L., Dos Santos, R. G. et al. · Journal of Clinical Psychopharmacology (2016)
Bouso, J. C., González, D., Fondevila, S. et al. · PLOS ONE (2012)
Davis, A. K., Streeter Barrett, F., Cosimano, M. P. et al. · Journal of Psychopharmacology (2022)
Ramaekers, J. G. · Psychopharmacology (2022)
Healy, C. J., Lee, K. A. · Chronic Stress (2021)
Mathai, D. S., Roberts, D. E., Nayak, S. M. et al. · Journal of Psychedelic Drugs (2025)
Fauvel, B., Strika-Bruneau, L., Piolino, P. · Psychology of Consciousness Theory Research and Practice (2023)
Monroy, M., Keltner, D. · Perspectives on Psychological Science (2022)
Barbosa, P., Strassman, R. J., da Silveira, D. X. et al. · Comprehensive Psychiatry (2016)
Barbosa, P., Tófoli, L.F., Bogenschutz, M. P. et al. · Frontiers in Psychiatry (2018)
Maia, L. O., Massarentti, C. M., Tófoli, L.F. · Psychopharmacology (2022)